The fund’s investment objective is to achieve capital growth through investment in UK equities. However, attention will be paid to maintaining a steady growth in income distribution. Investment will be in a balanced portfolio of good quality companies structured to produce a higher immediate income than is obtainable from funds concentrating entirely on capital growth. Investment will be in directly held transferable securities. The fund may also invest in collective investment schemes, warrants and money market instruments.
Name | % Net Assets |
---|---|
GlaxoSmithKline | 5.0% |
BP | 4.0% |
Vodafone Group | 3.7% |
HSBC Holdings | 3.5% |
Lloyds Banking Group | 3.2% |
AstraZeneca | 3.2% |
Legal & General Group | 3.1% |
Reed Elsevier | 3.1% |
Unilever | 2.7% |
Schroder Recovery Fund | 2.5% |
Key | % Net Assets |
---|---|
GlaxoSmithKline | 5.0% |
BP | 4.0% |
Vodafone Group | 3.7% |
HSBC Holdings | 3.5% |
Other | 83.8% |
Date | 02-Mar-2022 |
---|---|
NAV | 2,294.00p |
Currency | GBP |
Change | -43.00p |
% | -1.84% |
YTD change | 2,294.00p |
YTD % | n/a |
Fund Inception | 30/04/1987 |
---|---|
Fund Manager | Alex Breese |
TER | 1.67 (20-Jun-2012) |
Minimum Investment | |
---|---|
Initial | £1000 |
Additional | n/a |
Savings | £50 |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.02 |
Sharpe ratio | 0.09 |
You are here: research